Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Evaluating a Digital Diabetes Education Program Based on Individualized Carbohydrate Management
| NCT number | NCT04198935 |
| Other study ID # | 0000001 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | May 2020 |
| Est. completion date | August 2020 |
| Verified date | December 2019 |
| Source | Span Health |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The first line of treatment for patients with type 2 diabetes usually entails referral for
diabetes education which has been shown to improve outcomes. The National Diabetes Audit
2016-17 showed an increase in the percentage of patients with type 2 diabetes who are offered
a diabetes education program. Despite this, the percentage of recorded attendance was only
7%.
Digitally delivered interventions have the potential to solve the problem of adherence to
education programs. Digitally delivered diabetes prevention programs have been shown to have
higher participation than in-person programs. As a solution to this we propose a structured
diabetes education program based on individualized carbohydrate management delivered through
a mobile application. The clinical approach is based on multiple clinical trials
demonstrating its effectiveness and is in line with the most recent NICE guidelines.
The investigator interviewed a group of general practitioners and patients to identify the
target group most suited for this solution. Three groups of patients were identified who
would benefit the most from a digital diabetes education program. The first group are
patients who have declined face-to-face education for any reason. The second group are
patients who are on a waiting list for face-to-face education but will not receive it. The
third group are patients who have undergone in-person education but have not clinically
improved.
To evaluate the acceptability of this approach among patients with diabetes type 2 the
investigators will use a Net Promoter Score survey. Adherence to the program will be assessed
by measuring the percentage of people completing the whole 3 months. We will also evaluate
whether this approach improves patient outcomes as measured by NICE defined treatment targets
for glucose control, blood pressure and blood cholesterol. Secondary aims include comparing
healthcare resource utilization. Outcomes are to be measured at baseline and at the
completion of the 12 week program. Clinical outcomes to be measured are: body weight, blood
pressure, Haemoglobin A1c (HbA1c), total cholesterol, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol and triglycerides level.
| Status | Not yet recruiting |
| Enrollment | 100 |
| Est. completion date | August 2020 |
| Est. primary completion date | July 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Diagnosed with type 2 diabetes - Have access to and feel comfortable using a smart phone Exclusion Criteria: - Patients who cannot use a smart phone or mobile phone texting functions. - Patients on SGLT2 inhibitors (Gliflozins) - Patients taking insulin - Patients already undergoing face-to-face structured education at the time of the study - Patients with diagnosed heart failure or chronic kidney disease |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Adam Bataineh |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in weight | Change from baseline weight in kilograms at 3 months | 3 months | |
| Primary | Blood pressure | Change from baseline systolic blood pressure in millimeters of mercury (mmHg) at 3 months | 3 months | |
| Primary | Hemoglobin A1C (HbA1C) level | Change from baseline HbA1C level in mmol/mol at 3 months | 3 months | |
| Primary | Lipid profile | Change from baseline lipid profile (including total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides level in mg/dL) at 3 months | 3 months | |
| Primary | Participant's experience | To assess the experience of participants using a Net Promoter Score survey based on a 0 to 10 scale with higher scores indicating a more favorable outcome | 3 months | |
| Primary | Adherence to the the program | Adherence to the program will be assessed by measuring the percentage of the program completed by the participant.More than 80% of the program completed will be considered adherent to the program. | 3 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |